MOXICIP KT Eye Drops (Moxifloxacin 0.5% + Ketorolac tromethamine 0.5%)
Table of Content
India has experienced an exponential increase in the number of cataract surgeries. An estimated 0.5 million cataract surgeries were done in 1981–1982; this increased to 4.8 million in 2006 with 90% intraocular lens acceptance. Inflammation has always been accepted as a natural consequence of the cataract surgical procedures and also these procedures are associated with a risk of infection. These consequences are generally treated with anti-inflammatory (steroids) and anti-infective eye drops. But the adverse consequences associated with long term use of steroids and the resistance and efficacy issues associated with the use of older generation anti-infectives warrants the need for a combination wherein Power Will Breed Safety.
Moxicip KT contains Moxifloxacin, a genetically smart, broad spectrum fluoroquinolone and Ketorolac a potent anti-inflammatory and analgesic non-steroidal anti-inflammatory. The combination of these drugs has positive therapeutic effect on postoperative inflammation and prevention of postoperative infection following cataract surgery. Also the presence of an anti-inflammatory and antibiotic agent in a single ophthalmic product overcomes any potential 'washout effect' that may be seen when separate medications are used. In addition, the combination also leads to better compliance, patient comfort and safety. The reduced number of administrations with this combination may be of particular benefit for elderly patients, who make up the majority of cataract surgery cases.
Moxicip KT contains Moxifloxacin 0.5% (anti-infective) and Ketorolac 0.5% (anti-inflammatory non-steroidal). It is the World’s first antibiotic and NSAID combination to be preservative free and with HEC (Hydroxyethyl cellulose). HEC is a polymer which acts as a viscosity enhancer improving the retention time of the drug.
For NSAID-responsive inflammatory ocular conditions for which a NSAID is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
Dosage and Administration
One drop in affected eye three times a day
Moxicip KT: Highlights
- First a combination of
- Moxifloxacin: A broad spectrum, potent, 8 methoxy fluoroquinolone
- Ketorolac: A potent anti-inflammatory and analgesic agent
- A combination with HEC advantage which increases the drug retention time
- A combination with no preservative which results in no corneal toxicity
- A combination which can be used for wide array of indications
- A combination which will provide patient compliance and long-term usage.